Nurix Therapeutics Inc.

## Signal Note: Baker Bros. Initiates Large Position in Nurix Therapeutics (NRIX) **Note: The reported position value of ~$88.4B appears to be a data error — likely reflecting ~$88.4M based on recent NRIX share prices (~$19), which would represent a meaningful but plausible stake for Baker Bros.** Baker Bros. initiating a ~4.66M share position in Nurix is a high-conviction signal given their concentrated, fundamentally-driven approach in biotech; this likely reflects confidence in Nurix's targeted protein degradation platform, particularly lead asset NX-2127 (a BTK degrader for relapsed/refractory B-cell malignancies) and NX-5948, which has shown differentiated activity in both hematologic cancers and potential in autoimmune indications — a space attracting significant M&A interest.